Autonomous truck company with Houston routes goes public

on a roll

Kodiak Robotics has formed Kodiak AI, whose stock now trades on the Nasdaq market. Photo via kodiak.ai.

Kodiak Robotics, a provider of AI-powered autonomous vehicle technology, has gone public through a SPAC merger and has rebranded as Kodiak AI. The company operates trucking routes to and from Houston, which has served as a launchpad for the business.

Privately held Kodiak, founded in 2018, merged with a special purpose acquisition company — publicly held Ares Acquisition Corp. II — to form Kodiak AI, whose stock now trades on the Nasdaq market.

In September, Mountain View, California-based Kodiak and New York City-based Ares disclosed a $145 million PIPE (private investment in public equity) investment from institutional investors to support the business combo. Since announcing the SPAC deal, more than $220 million has been raised for the new Kodiak.

“We believe these additional investments underscore our investors’ confidence in the value proposition of Kodiak’s safe and commercially deployed autonomous technology,” Don Burnette, founder and CEO of Kodiak, said in a news release.

“We look forward to leading the advancement of the commercial trucking and public sector industries,” he added, “and delivering on the exciting value creation opportunities ahead to the benefit of customers and shareholders.”

Last December, Kodiak debuted a facility near George Bush Intercontinental/Houston Airport for loading and loading driverless trucks. Transportation and logistics company Ryder operates the “truckport” for Ryder.

The facility serves freight routes to and from Houston, Dallas and Oklahoma City. Kodiak’s trucks currently operate with or without drivers. Kodiak’s inaugural route launched in 2024 between Houston and Dallas.

One of the companies using Kodiak’s technology is Austin-based Atlas Energy Solutions, which owns and operates four driverless trucks equipped with Kodiak’s driver-as-a-service technology. The trucks pick up fracking sand from Atlas’ Dune Express, a 42-mile conveyor system that carries sand from Atlas’ mine to sites near customers’ oil wells in the Permian Basin.

Altogether, Atlas has ordered 100 trucks that will run on Kodiak’s autonomous technology in an effort to automate Atlas’ supply chain.

From Your Site Articles
Earlier this month, Autonomix Medical went public. The company's technology is geared toward treating pain stemming from pancreatitis and pancreatic cancer. Photo via nasdaq.com

Houston-area med device company grosses $11.1M in recent IPO

going public

The Woodlands-based medical device company Autonomix Medical grossed more than $11.1 million in its recent IPO.

The company’s stock now trades on the NASDAQ market under the symbol AMIX. On February 1, company officials range the NASDAQ’s closing bell. The stock closed February 5 at $5.60 per share.

The NASDAQ listing “represents a pivotal moment in the growth of our [company] and a significant corporate milestone leading to what we believe will be an exciting future for Autonomix,” says Lori Bisson, the company’s CEO.

In the IPO, Autonomix sold nearly 2.24 million shares of common stock at $5 each. The gross amount raised excludes sales commissions and other expenses.

In a January 19 filing with the U.S. Securities and Exchange Commission (SEC), Autonomix had eyed gross IPO proceeds of more than $21.2 million — nearly half of what the company actually raised — from the sale of up to 4 million shares.

For the six-month period ended September 30, 2023, Autonomix tallied a net loss of $6.9 million and a deficit of nearly $30.5 million.

Outside investors BioStar Ventures (with a 15 percent pre-IPO stake) and Tricord Holdings (5.5 percent), according to SEC documents. Before the IPO, seven Autonomix executives and directors controlled 50.6 percent of the company’s common stock.

The first medical device being developed by Autonomix, founded in 2014, is a catheter-based microchip that the company says can detect and differentiate neural signals with about 3,000 times greater sensitivity than current technology.

On its website, Autonomix cites a potential $100 billion global market for its technology.

Initially, Autonomix’s technology is geared toward treating pain stemming from pancreatitis and pancreatic cancer. Other uses for the technology, protected by dozens of patents, include management of post-surgery pain, treatment of high blood pressure, and treatment of organ-related conditions.

A day after the January 29 IPO, Autonomix announced it had wrapped up an $8 million all-stock deal to regain exclusive worldwide rights for use of its technology in the cardiology sector. In December 2021, Autonomix granted a license to Impulse Medical for use of its technology for cardiac purposes. In exchange for 1.6 million Autonomix shares, Impulse sold back those rights to Autonomix.

“Regaining the cardiology rights to our innovative technology broadens our development opportunities and provides further optionality related to our development strategy moving forward. Looking ahead, we remain focused on our pancreatic cancer pain development program and are on track to commence our first-in-human clinical study this quarter,” Bisson says.

Autonomix says its catheter-based sensing technology is designed to sense neural signals associated with pain or disease and then target those nerves for treatment.

“Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness,” say the company, “and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston neighbor named richest small town in Texas for 2025

Ranking It

Affluent Houston neighbor Bellaire is cashing in as the richest small town in Texas for 2025, according to new study from GoBankingRates.

The report, "The Richest Small Town in Every State," used data from the U.S. Census Bureau's American Community Survey to determine the 50 richest small towns in America based on their median household income.

Of course, Houstonians realize that describing Bellaire as a "small town" is a bit of misnomer. Located less than 10 miles from downtown and fully surrounded by the City of Houston, Bellaire is a wealthy enclave that boasts a population of just over 17,000 residents. These affluent citizens earn a median $236,311 in income every year, which GoBankingRates says is the 11th highest household median income out of all 50 cities included in the report.

The average home in this city is worth over $1.12 million, but Bellaire's lavish residential reputation often attracts properties with multimillion-dollar price tags.

Bellaire also earned a shining 81 livability score for its top quality schools, health and safety, commute times, and more. The livability index, provided by Toronto, Canada-based data analytics and real estate platform AreaVibes, said Bellaire has "an abundance of exceptional local amenities."

"Among these are conveniently located grocery stores, charming coffee shops, diverse dining options and plenty of spacious parks," AreaVibes said. "These local amenities contribute significantly to its overall appeal, ensuring that [residents'] daily needs are met and offering ample opportunities for leisure and recreation."

Earlier in 2025, GoBankingRates ranked Bellaire as the No. 23 wealthiest suburb in America, and it's no stranger to being named on similar lists comparing the richest American cities.

---

This article originally appeared on CultureMap.com.

How a Houston startup is taking on corrosion, a costly climate threat

now streaming

Corrosion is not something most people think about, but for Houston's industrial backbone pipelines, refineries, chemical plants, and water infrastructure, it is a silent and costly threat. Replacing damaged steel and overusing chemicals adds hundreds of millions of tons of carbon emissions every year. Despite the scale of the problem, corrosion detection has barely changed in decades.

In a recent episode of the Energy Tech Startups Podcast, Anwar Sadek, founder and CEO of Corrolytics, explained why the traditional approach is not working and how his team is delivering real-time visibility into one of the most overlooked challenges in the energy transition.

From Lab Insight to Industrial Breakthrough

Anwar began as a researcher studying how metals degrade and how microbes accelerate corrosion. He quickly noticed a major gap. Companies could detect the presence of microorganisms, but they could not tell whether those microbes were actually causing corrosion or how quickly the damage was happening. Most tests required shipping samples to a lab and waiting months for results, long after conditions inside the asset had changed.

That gap inspired Corrolytics' breakthrough. The company developed a portable, real-time electrochemical test that measures microbial corrosion activity directly from fluid samples. No invasive probes. No complex lab work. Just the immediate data operators can act on.

“It is like switching from film to digital photography,” Anwar says. “What used to take months now takes a couple of hours.”

Why Corrosion Matters in Houston's Energy Transition

Houston's energy transition is a blend of innovation and practicality. While the world builds new low-carbon systems, the region still depends on existing industrial infrastructure. Keeping those assets safe, efficient, and emission-conscious is essential.

This is where Corrolytics fits in. Every leak prevented, every pipeline protected, and every unnecessary gallon of biocide avoided reduces emissions and improves operational safety. The company is already seeing interest across oil and gas, petrochemicals, water and wastewater treatment, HVAC, industrial cooling, and biofuels. If fluids move through metal, microbial corrosion can occur, and Corrolytics can detect it.

Because microbes evolve quickly, slow testing methods simply cannot keep up. “By the time a company gets lab results, the environment has changed completely,” Anwar explains. “You cannot manage what you cannot measure.”

A Scientist Steps Into the CEO Role

Anwar did not plan to become a CEO. But through the National Science Foundation's ICorps program, he interviewed more than 300 industry stakeholders. Over 95 percent cited microbial corrosion as a major issue with no effective tool to address it. That validation pushed him to transform his research into a product.

Since then, Corrolytics has moved from prototype to real-world pilots in Brazil and Houston, with early partners already using the technology and some preparing to invest. Along the way, Anwar learned to lead teams, speak the language of industry, and guide the company through challenges. “When things go wrong, and they do, it is the CEO's job to steady the team,” he says.

Why Houston

Relocating to Houston accelerated everything. Customers, partners, advisors, and manufacturing talent are all here. For industrial and energy tech startups, Houston offers an ecosystem built for scale.

What's Next

Corrolytics is preparing for broader pilots, commercial partnerships, and team growth as it continues its fundraising efforts. For anyone focused on asset integrity, emissions reduction, or industrial innovation, this is a company to watch.

Listen to the full conversation with Anwar Sadek on the Energy Tech Startups Podcast to learn more:

---

Energy Tech Startups Podcast is hosted by Jason Ethier and Nada Ahmed. It delves into Houston's pivotal role in the energy transition, spotlighting entrepreneurs and industry leaders shaping a low-carbon future.

This article originally appeared on our sister site, EnergyCapitalHTX.com.

These 50+ Houston scientists rank among world’s most cited

science stars

Fifty-one scientists and professors from Houston-area universities and institutions were named among the most cited in the world for their research in medicine, materials sciences and an array of other fields.

The Clarivate Highly Cited Researchers considers researchers who have authored multiple "Highly Cited Papers" that rank in the top 1percent by citations for their fields in the Web of Science Core Collection. The final list is then determined by other quantitative and qualitative measures by Clarivate's judges to recognize "researchers whose exceptional and community-wide contributions shape the future of science, technology and academia globally."

This year, 6,868 individual researchers from 60 different countries were named to the list. About 38 percent of the researchers are based in the U.S., with China following in second place at about 20 percent.

However, the Chinese Academy of Sciences brought in the most entries, with 258 researchers recognized. Harvard University with 170 researchers and Stanford University with 141 rounded out the top 3.

Looking more locally, the University of Texas at Austin landed among the top 50 institutions for the first time this year, tying for 46th place with the Mayo Clinic and University of Minnesota Twin Cities, each with 27 researchers recognized.

Houston once again had a strong showing on the list, with MD Anderson leading the pack. Below is a list of the Houston-area highly cited researchers and their fields.

UT MD Anderson Cancer Center

  • Ajani Jaffer (Cross-Field)
  • James P. Allison (Cross-Field)
  • Maria E. Cabanillas (Cross-Field)
  • Boyi Gan (Molecular Biology and Genetics)
  • Maura L. Gillison (Cross-Field)
  • David Hong (Cross-Field)
  • Scott E. Kopetz (Clinical Medicine)
  • Pranavi Koppula (Cross-Field)
  • Guang Lei (Cross-Field)
  • Sattva S. Neelapu (Cross-Field)
  • Padmanee Sharma (Molecular Biology and Genetics)
  • Vivek Subbiah (Clinical Medicine)
  • Jennifer A. Wargo (Molecular Biology and Genetics)
  • William G. Wierda (Clinical Medicine)
  • Ignacio I. Wistuba (Clinical Medicine)
  • Yilei Zhang (Cross-Field)
  • Li Zhuang (Cross-Field)

Rice University

  • Pulickel M. Ajayan (Materials Science)
  • Pedro J. J. Alvarez (Environment and Ecology)
  • Neva C. Durand (Cross-Field)
  • Menachem Elimelech (Chemistry and Environment and Ecology)
  • Zhiwei Fang (Cross-Field)
  • Naomi J. Halas (Cross-Field)
  • Jun Lou (Materials Science)
  • Aditya D. Mohite (Cross-Field)
  • Peter Nordlander (Cross-Field)
  • Andreas S. Tolias (Cross-Field)
  • James M. Tour (Cross-Field)
  • Robert Vajtai (Cross-Field)
  • Haotian Wang (Chemistry and Materials Science)
  • Zhen-Yu Wu (Cross-Field)

Baylor College of Medicine

  • Nadim J. Ajami (Cross-Field)
  • Biykem Bozkurt (Clinical Medicine)
  • Hashem B. El-Serag (Clinical Medicine)
  • Matthew J. Ellis (Cross-Field)
  • Richard A. Gibbs (Cross-Field)
  • Peter H. Jones (Pharmacology and Toxicology)
  • Sanjay J. Mathew (Cross-Field)
  • Joseph F. Petrosino (Cross-Field)
  • Fritz J. Sedlazeck (Biology and Biochemistry)
  • James Versalovic (Cross-Field)

University of Houston

  • Zhifeng Ren (Cross-Field)
  • Yan Yao (Cross-Field)
  • Yufeng Zhao (Cross-Field)
  • UT Health Science Center Houston
  • Hongfang Liu (Cross-Field)
  • Louise D. McCullough (Cross-Field)
  • Claudio Soto (Cross-Field)

UTMB Galveston

  • Erez Lieberman Aiden (Cross-Field)
  • Pei-Yong Shi (Cross-Field)

Houston Methodist

  • Eamonn M. M. Quigley (Cross-Field)
View All Listings